Objective: To conduct a cross-national validation of the Scales for Outcomes in Parkinson's Disease-PsychoSocial questionnaire (SCOPA-PS) in four Latin American Countries. Methods: Data quality (missing items), scale assumptions (item-test correlation), internal consistency (Cronbach's alpha, item homogeneity), factor structure, content validity, and precision (standard error of measurement, SEM) of the scale were explored, as was convergent validity with motor symptoms (Clinical Impression of Severity Index [CISI-PD], Scales for Outcomes in Parkinson's Disease-Motor Scale), emotional status (Hospital Anxiety and Depression Scale) and health-related quality of life (Parkinson Disease Questionnaire-39). Known-groups validity was studied by category of severity, based on Hoehn and Yahr staging (HY), CISI-PD, and disease duration. Results: Three hundred thirty-one Parkinson's disease (PD) patients with usable data participated (mean age 64.7 years; 42.3% female; mean PD duration 8.5 years; HY, 1 to 5). Data quality (missing items <10%), scale assumptions (item-total correlation = 0.43 -0.71) and internal consistency of SCOPA-PS (Cronbach's alpha = 0.87; item homogeneity = 0.38) were satisfactory. Factor analysis suggested a unifactorial structure. High convergent validity was found for depression (rS = 0.61), anxiety (rS = 0.62), and health-related quality of life (rS = 0.82). Knowngroups validity analyses indicated a gradual influence of severity category and disease duration on SCOPA-PS scores (P < 0.0001). SEM value was 8.24 (7 to 12 in previous studies). These magnitudes may be indicative of the threshold for a real change and a minimum important difference.
Introduction
A progressive neurologic disease affecting approximately 2% of the population aged 65 years and over, Parkinson's disease (PD) ranks as the second leading neurodegenerative and one of the most burdensome diseases [1, 2] . Over the last few years, greater attention has been devoted to nonmotor symptoms of PD. Psychological nonmotor symptoms including depression, apathy, social embarrassment, loneliness, and increasing dependence on others for everyday activities have scarcely been addressed in the literature. There is evidence to suggest that in addition to the motor disorder, the psychological manifestations of PD are major factors accounting for disability and deterioration in quality of life. For instance, low self-reported satisfaction with social support is linked to higher depression, anxiety, and stress among PD patients [3] . In addition, depression is the strongest determinant of health-related quality of life (HRQoL) in PD patients [4] . In this connection, experts have acknowledged the need for specific instruments to measure PD's psychosocial outcomes and HRQoL [5, 6] .
A recent review by Dowding and Claire [7] concluded that the lack of uniformity in the choice of HRQoL tools used in PD studies renders comparison of results difficult. Furthermore, the few studies available have been undertaken in developed nations, meaning that there are almost no assessment tools validated for Asia, Africa, or South America [8, 9] .
This study presents a cross-cultural adaptation and multinational validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) [10] in four Latin American countries (Argentina, Brazil, Ecuador, and Paraguay). The designated goals of this study were: 1) to obtain a cross-culturally adapted version of the SCOPA-PS for all participant countries; and 2) to analyze the psychometric properties of the scale in a wide multinational sample, including some specific analyses per country.
Patients and Methods

Patients
The sample was composed of consecutive PD outpatients from the participant centers. Patients were assessed in the period from March through August 2006. Inclusion criteria were: diagnosis of PD as per the UK Parkinson's Disease Society Brain Bank Criteria [11] , age 30 years or over at disease onset, and Hoehn and Yahr stages (HY) 1 to 5 [12] . Exclusion criteria were: 1) parkinsonism other than PD; 2) concomitant severe condition, acute disorder or injury, pharmacological effect (e.g., dopamine antagonists), sensorial deficit (e.g., blindness), or sequela status (e.g., hemiplegia) potentially interfering with evaluation of PD manifestations and impact; 3) inability to read or understand questionnaires; and 4) refusal to participate. The local Institutional Review Board at every participating center approved the study protocol. Informed consent in accordance with local ethical guidelines was obtained from all participants.
Assessments
In addition to the standard PD evaluation measures, a sociodemographic questionnaire, the SCOPA-PS, and additional instruments for validity analysis purposes were administered to all participants. HY and the Clinical Impression of Severity Index (CISI-PD) [13] were used to determine PD stage and global severity, respectively. Motor aspects were appraised by means of the Scales for Outcomes in Parkinson's Disease-Motor Scale (SCOPA-MS) [14] . The Cumulative Illness Rating Scale Geriatric version (CIRS-G) [15] was applied to assess comorbidity. In addition, the Hospital Anxiety and Depression Scale (HADS) [16] was used for anxiety and depression screening. HRQoL was assessed by means of the Parkinson Disease Questionnaire-39 (PDQ-39) [17, 18] .
HY staging encompasses five stages of growing severity, from HY 1 (unilateral symptoms) to HY 5 (wheelchair or bed-bound). In this study, the original HY [12] was used and severity levels were collapsed into the following three major categories: mild (stages 1 and 2), moderate (stage 3), and severe (stages 4 and 5).
The CISI-PD assesses clinical impression of severity with respect to four items, namely, motor signs, disability, motor complications, and cognitive status. Each item is scored on a seven-point Likert scale (from 0, normal, to 6, very severe), and the total score is reached by summing all four items. For validity study purposes, the scale range was split into three severity groups, mild (1-7), moderate (8) (9) (10) (11) (12) (13) (14) , and severe (Ն15).
The PDQ-39 is a self-administered 39-item scale. Items refer to self-reported difficulty in respect of each item during the previous month. Items are scored on a five-point Likert scale, with higher scores indicating greater difficulty (0: never to 4: always). The questionnaire is made up of eight dimensions: mobility (10 items), activities of daily living (six items), emotional well-being (six items), stigma (four items), social support (three items), cognition (four items), communication (three items), and bodily discomfort (three items). For each domain, the summed item scores are transformed into a percentage of the maximum possible total score. The PDQ-39 summary index (SI) is the sum obtained from the sum of all such domain scores divided by the number of domains.
The SCOPA-MS is a 21-item scale covering three domains, i.e., motor examination (10 items), activities of daily living (ADL) (seven items), and motor complications (four items). All items are scored on a four-point Likert scale (0: normal; 3: severe). Total scores are obtained by summing item scores: the higher the score, the more severe the motor disorder.
The CIRS-G was used to assess comorbidity. CIRS-G measures the severity of simultaneous diseases in 14 organ systems, and is administered by a physician. Items are answered on a four-point Likert scale (0: none; 4: extremely severe-immediate treatment required/end organ failure/severe impairment in function), with the total score being the result of summing the individual item scores. The CIRS-G has been successfully used to assess comorbidity in PD patients [19] .
The strong association between depression/anxiety and PD justified HADS administration [20] . This scale comprises 14 items, 7 addressing anxiety and 7 depression. Items are answered on a four-point Likert scale (0: no problem; 3: severe problem). Anxiety and depression scores (HADS-Anx, HADS-Dep) are computed by summing the items in each construct. Eleven or more points on either of the two subscales is evidence of clinically significant levels of anxiety or depression [21] .
The SCOPA-PS is a self-administered, 11-item questionnaire assessing psychosocial functioning during the preceding month. Items are scored on a four-point Likert scale, with higher scores denoting greater difficulty (0: not at all; 3: very much). The summary index-used for analysis purposes in this study-is obtained by summing up direct item scores transformed into percentage values. Previous validation studies have proved satisfactory [8, 10] .
Translation and Back-Translation
The original English-language version [10] was adapted to Spanish as follows: two bilingual contributors agreed on a Spanish version based on the original English questionnaire. A panel of experts reviewed and revised the Spanish version until agreement was reached on its linguistic and conceptual equivalence vis-à-vis the original. Both original English and Spanish version were then forwarded to the Latin American coresearchers, who proceeded to adjust the instrument to the local Spanish, Portuguese, and Guarani languages. Back-translations from local versions into Spanish (Spain) were subsequently sent to coauthor PMM, and revised until considered equivalent.
Analyses
Data quality and acceptability were determined by percentage of missing data per item (criterion <10%) and fully computable scores (criterion >90%) [22] , difference between observed and possible scores, mean to median differences (suggested criterion <15% maximum score), ceiling and floor effects (criterion <15%) [23] , skewness (criterion -1 to +1) [24] , and kurtosis (criterion -1 to +1) [25] .
Item-total correlation corrected for overlap (criterion r Ն 0.30) [26] was calculated to substantiate scaling assumptions. Internal consistency was explored by means of Cronbach's alpha (criterion Ն0.70) [27] and item homogeneity index (mean of interitem correlation; criterion >0.30) [28] . The content validity index was determined by the proportion of experts in a panel, who rated the scale as representative and relevant to the construct being measured. A letter with the scale and assessment materials was forwarded to 10 experts. Experts were asked to rate the SCOPA-PS items on a four-point Likert scale (1: not relevant; 4: very relevant and concise). The content validity index is the proportion of items rated as 3 or 4 by the board of experts (criterion Ն75%) [29, 30] .
Exploratory factor analysis was performed using the principal components method. Adequacy of the correlation matrix was studied by reference to Bartlett's statistic (criterion: P Յ 0.05) and the Kaiser-Meyer-Olkin criterion (KMO; criterion Ն0.5) test. Explained variance of dimensions with eigenvalues of over 1 was explored. Parallel analysis was used to determine the number of dimensions retained [31] . Loading per item and reliability estimates [32] (suggested criterion: Ն0.80) of the resulting matrix were obtained. Finally, mean fitted residuals (criterion < 1 n ) and the root mean square residuals (RMSR) (criterion <0.06) were analyzed. Factor analysis was performed using the Factor statistical package [33] .
Convergent validity was estimated by correlating SCOPA-PS with another HRQoL measure (PDQ-39), PD-symptom scales (SCOPA-MS, CISI-PD), anxiety and depression (HADS), and disease stage (HY) and duration. We hypothesized that SCOPA-PS correlation would be high (rS Ն 0.60) as against PDQ-39 and HADS, and moderate as against SCOPA-MS, CISI-PD, disease severity (categories based on HY) and with disease duration (rS = 0.30 -0.59). Given that variables were nonnormally distributed, Spearman's rank correlation coefficient was used. Fisher's Z statistic was used to compare correlation coefficients in per-country convergent validity analyses.
Known-groups validity analyses entailed breaking down SCOPA-PS scores by HY and CISI-PD severity level, and category of disease duration (<5 y., 5-9 years, Ն10 years).
A stepwise regression analysis model was constructed in order to identify the association between sociodemographic and disease-related factors and psychosocial functioning in PD. In order to avoid colinearity, correlation coefficients higher than 0.40 between independent variables within a model were not permitted. In the latter case, alternative regression models were calculated separately for both independent variables.
The standard error of measurement for a single observed score (standard error of the mean SEM SD [ ]= − 1 α ) [34] and its 95% upper confidence limit (1.96 ¥ SEM) [23] were calculated in order to assess the precision of the assessed scale (suggested criterion: SEM Յ SD/2) [35] .
In addition to the analysis in the pooled sample, major psychometric attributes (internal consistency, precision, and convergent validity) were explored by country.
Results
A sample of 338 participants met the inclusion criteria. For analysis purposes, an individual's mean was used to impute one missing SCOPA-PS value [36] , and seven patients with two or more missing values were not included. Consequently, the data referred to a total of 331 patients (42.30% female; mean age Ϯ SD: 64.68 Ϯ 10.76 y.). Mean disease duration at the date of assessment was 8.45 Ϯ 6.04 (range: 0-43), and median HY was 3.0 (interquartile range: 2-3) ( Table 1) .
SCOPA-PS item 5 (sexuality) registered 69 missing values, 46 corresponding to single, widowed, and divorced participants. Hence, item 5 was missing in only 9.87% of married participants. The proportion of missing values for the remaining SCOPA-PS items was 0.59% to 2.07%. The observed scoring range covered the possible range for all items and for the total score. Neither floor nor ceiling effects were observed (0.91%); skewness was 0.39 and kurtosis -0.49. Item-total correlation coefficients ranged from 0.43 (item 10) to 0.71 (item 9). Data quality, acceptability, and scale assumptions estimates are shown in Table 2 .
Cronbach's alpha was 0.87 and item homogeneity index, 0.38. Table 3 shows the internal consistency estimates per country. Although estimates were numerically similar for all countries, they were nonetheless slightly higher for the Argentine sample (0.92; 0.49, respectively). Content validity index for the SCOPA-PS was 92.93% (panel response rate 90%). Qualitative assessment by the panel of experts raised a few minor drafting issues including: 1) polysemic use of the Spanish verb "relacionarse" in the items 3, 4, and 5 that may involve redundancy and lack of clarity; 2) emotional effect of the test in the respondent given the negative valence of most items; and 3) item 1 may be not applicable to all patients as some of them have no household or work duties assigned.
In view of the nonnormally distributed data (KolmogorovSmirnov test, P < 0.01) and item kurtosis (Table 2) , a principal components factor analysis based on polychoric correlations was conducted [37] . The KMO statistic exceeded 0.5 (KMO = 0.904), and Bartlett's test was significant (c 2 55 = 1587.1, P < 0.001), indicating the adequacy of the correlation matrix. Two factors with eigenvalues higher than 1 accounted for a cumulative variance of 57.68%. Nevertheless, parallel analysis made it advisable for a single dimension to be retained, accounting for 48.58% of variance. The reliability estimate of the factor was 0.89. All item loadings were above 0.50. The mean fitted residual was below the criterion (-0.05), though the RMSR was slightly above the criterion (RMSR = 0.079).
Convergent validity results are shown in Table 4 . Summary indices of the PDQ-39 and SCOPA-PS correlated highly (rS = 0.82). Correlation between SCOPA-PS and anxiety (rS = 0.62) and depression (rS = 0.61) as measured by HADS, was also high. In addition, correlations with SCOPA-MS (rS = 0.51) and CISI-PD (rS = 0.57) were moderate, as they were with disease stage (rS = 0.45) and duration (rS = 0.31). Correlation with the CIRS-G (rS = 0.16) was weak. These results were consistent across countries, as shown by Fisher's Z test comparing maximum and minimum correlation coefficients per variable. Results were not significantly different for all estimates excepting bodily discomfort, cognitive status, and Hoehn and Yahr staging (Fisher's Z, P < 0.05) ( Table 4) . Known-groups validity analyses showed that SCOPA-PS scores increased gradually with HY and CISI-PD-based severity levels, and with disease duration broken down by 5-year periods (Kruskal-Wallis test, P < 0.0001).
Given that two pairs of relevant variables registered correlations of over 0.40 (disease duration with HY, rS = 0.45; and HADS-Dep with HADS-Anx, rS = 0.62), four regression models were calculated, introducing and withdrawing one of the variables in each pair at a time ( Table 5 ). The four regression models (F = 80.15 -106.25; R 2 : 0.42-0.49; all P < 0.0001) showed that age, duration, HY, and HADS (both depression and anxiety) had an independent effect on psychosocial adjustment (SCOPA-PS) ( Table 5 ).
The SEM was 8.24 (upper 95% CI = 16.14). Precision by country ranged from 6.83 (95% CI 13.38) to 8.68 (95% CI 17.02) ( Table 3) .
Discussion
According to our results, the psychometric properties of the SCOPA-PS are consistent with the findings of previous studies [8, 10] (see Table 6 for comparison). It should be noted that the present study doubles the sample size of previous surveys and is the first to include a significant number of severe PD cases. In addition, it is also the first to be conducted in an international setting and to explore some new features of the scale (specifically, item homogeneity, content validity, and factor structure).
In line with previous studies [8, 10] , data quality indices were above the standard threshold for full-computable data to be considered acceptable, with the single exception of item 5 (sexuality). Although most patients are generally assumed to be reluctant to answer this question, the data quality of the scale could nevertheless be improved by an additional instruction as to when this item should be administered. Our data suggest that in cases where only individuals with known partners are considered, the rate of missing values fits the criterion.
Scale acceptability proved satisfactory as assessed by the difference between observed and possible ranges, score variation attributable to mean-median differences, absence of floor and ceiling effects, and skewness according to standard criteria. Scaling assumptions were likewise appropriate according to the item-total correlation criterion. The internal consistency of the scale was adequate and consistent with previously reported values [8, 10] , and when approached via item homogeneity, internal consistency again proved to be above the suggested threshold. The content validity index suggests that the scale is highly relevant and concise, though qualitative assessment by the panel of experts did raise a few minor drafting issues.
Exploratory factor analysis and parallel analysis suggested a one-factor solution, which strengthens the scale's construct validity. Insofar as construct convergent validity was concerned, our results largely supported the hypotheses posed, inasmuch as SCOPA-PS displayed strong associations with HRQoL, depression, and anxiety, and moderate associations with PD symptoms, PD staging, and disease duration. These results mimic those of the original study, which also reported high convergent validity between PDQ-39, HADS-Anx, and HADS-Dep, and SCOPA-PS. Nevertheless, the study by Carod-Artal et al. [8] reported a moderate association with depression and anxiety, a fact that may be attributable to differential distribution of PD severity in their sample (Table 6 ).
Construct validity was additionally supported by knowngroups analyses, which demonstrated gradual and significant reductions in psychosocial functioning (i.e., an increase in SCOPA-PS scores) with longer disease duration and higher severity categories. This finding is in line with the discriminative analysis reported in the Brazilian study [8] . Finally, regression analyses showed that depression, anxiety, and HY were the variables that accounted for most SCOPA-PS scoring variability ( Table 5 ). The precision of the scale proved satisfactory, with the SEM value being below the suggested criterion (SD/2). Moreover, the SEM reported in our study was similar to that reported by the original authors and considerably lower than that reported by Carod-Artal et al. [8] (Table 6 ). Taking into account the SEM values obtained from the three studies available, one could conclude that a change of 7 to 12 (around 10%) in the SCOPA-PS summary index could be considered a real change and a minimum important difference [35, 38] .
In some aspects, the study's limitations are mainly related to the sample's variability among the participant countries. For instance, most HY 5 participants came from Ecuador, while Argentinean participants tended to be concentrated in HY stages 1 through 3. In addition, participants from Argentina tended to live in rural areas more frequently than participants from other countries did. It could be postulated that these differences may be connected with the high levels of reliability and precision showed by Argentinean participants. It could be argued that respondents at low PD stages are more reliable in reporting their own psychosocial functioning, which is consistent with better cognitive functioning at early PD stages [39] . As a matter of fact, Argentinean patients scored significantly better in the CISI-PD cognitive status domain (0.48 vs. 1.00-1.76, Kruskal-Wallis, P < 0.0001). On the other hand, the removal of rural residents did not alter their average SCOPA-PS score as it has been found in other countries [40] . Finally, the high precision and reliability in Argentineans may rather be a byproduct of their lower SCOPA-PS score (34.53 vs. 35.00-43.67) as the scale seems to be more internally consistent in the lower half score range than in the higher (Cronbach alpha, 0.67 vs. 0.55). Although sample variability may limit the internal validity of the study, it favors its external validity. Test-retest reliability and responsiveness of the measure were not assessed.
In summary, the tested Latin American versions of the SCOPA-PS are reliable and valid for assessing psychosocial adjustment among patients with mild, moderate, and severe PD.
